1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

Biogen/Eisai Will Explore Volume-Based Discounts For Aduhelm In Medicare

 
• By Cathy Kelly

Deal with Veterans Administration also expected; companies say they will work with payers to ‘address’ pricing if patient population and uptake for their Alzheimer's drug are greater than expected.

Patient From Early Stage Aducanumab Trial At Left • Source: Alamy

Biogen, Inc. and partner Eisai Co., Ltd. are open to providing the Medicare program volume-based discounts on their recently approved drug for Alzheimer’s disease in recognition of the financial burden the $56,000 per year treatment could impose on the program.

The companies set the launch price for the drug based on their “belief in the impact of treatment as well as the size of the appropriate patient population based on the entry criteria of our clinical trials,” they explained in a statement released on 23 June

More from Medicare

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Proposed HHS Budget Would Eliminate Medicare Negotiation Program Start-Up Funding

 
• By Cathy Kelly

The preliminary budget document supports legislation clawing back funds appropriated for the program.

Medicare Price Negotiation: Trump Order Adds Momentum To ‘Pill Penalty’ Fix

 
• By Cathy Kelly

Wide-ranging executive order to lower drug prices also hints at changes in upcoming guidance on the Medicare price negotiation program but few other potentially impactful near-term actions.

More from Government Payers

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By Cathy Kelly

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Stand-Alone PDP Market Lives to Fight Another Day, Enrollment Data Shows

 
• By Leslie Small

No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.

Companies Advised To Assess Potential Impacts Of Landmark Global Pandemic Treaty

 
• By Neena Brizmohun

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.